证券代码：002584 证券简称：西陇科学 公告编号：2025-055 西陇科学股份有限公司 关于母公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、 担保情况概述 西陇科学股份有限公司（以下简称"西陇科学"或"公司"）第六届董事会第八 次会议审议通过了《关于公司及子公司对 2025 年度融资授信提供担保的议案》。 2025 年度，根据公司及子（孙）公司的生产经营和资金需求情况，公司及子（孙） 公司为合并报表范围内公司向金融机构申请融资授信提供担保，担保额度总计不 超过人民币 37.5 亿元。具体如下： 公司为纳入合并报表范围的子（孙）公司向金融机构申请融资授信提供担保， 总额不超过人民币20.85亿元，其中对最近一期资产负债率小于等于70%的子（孙） 公司担保额度不超过人民币 16.35 亿元，对最近一期资产负债率超 70%的子（孙） 公司担保额度不超过人民币 4.5 亿元；子（孙）公司为合并范围内其他子（孙） 公司向金融机构申请融资授信提供担保，总额不超过人民币 0.55 亿元，其中对最 近一期资产负债率小于等于 70%的 ...

Core Viewpoint - The announcement details a change in the equity holdings of the controlling shareholders of Xilong Science Co., Ltd., indicating a reduction in their shareholding percentage without altering the control of the company [3][4]. Group 1: Shareholding Changes - The controlling shareholders, including Huang Weibao, Huang Zhenkai, and Huang Zhenjie, have reduced their total shareholding from 149,844,722 shares to 146,304,022 shares, resulting in a decrease in their combined holding percentage from 25.605% to 25.000% [3][4]. - This reduction in shareholding touches upon the 1% and 5% integer multiples, which is significant for regulatory reporting [3][4]. Group 2: Compliance and Disclosure - The share reduction was pre-disclosed in accordance with relevant regulations, and the actual reduction aligns with previously disclosed intentions and commitments [3][4]. - The company has ensured that the information disclosed is accurate and complete, with no misleading statements or omissions [1][2].

证券代码：002584 证券简称：西陇科学 公告编号：2025-054 3、本次减持事项已按照有关规定进行了预披露，本次实际减持情况与此前披露 的意向、承诺及减持计划一致。 2025年9月23日公司在《中国证券报》、《证券时报》、《上海证券报》、《证 券日报》和巨潮资讯网披露了《关于部分实际控制人减持股份的预披露公告》（公 告编号：2025-047），控股股东黄伟波先生、黄伟鹏先生、黄侦凯先生和黄侦杰先 生自减持预披露公告之日起 15 个交易日之后的三个月内，以集中竞价交易减持所持 公司股份合计不超过5,852,100 股（占公司总股本的 1.00%），以大宗交易减持所持 公司股份合计不超过11,704,300 股（占公司总股本的 2.00%)。 公司现收到控股股东黄伟波先生、黄侦凯先生、黄侦杰先生出具的《关于减持 公司股份的告知函》及其与一致行动人出具的《简式权益变动报告书》，获悉控股 股东黄伟波先生、黄侦凯先生、黄侦杰先生于2025年10月29日至2025年10月31日期 间以集中竞价方式减持公司股份3,540,700股，占公司总股本的 0.605%。本次减持后， 控股股东及其一致行动人合计持有公司股份由 ...

股票代码：002584 股票上市地点：深圳证券交易所 信息披露义务人：黄伟波、黄侦凯、黄侦杰 通讯地址：广州市黄埔区科学城新瑞路 6 号 信息披露义务人之一致行动人：黄伟鹏、黄少群 通讯地址：广州市黄埔区科学城新瑞路 6 号 股份变动性质：减少 西陇科学股份有限公司 简式权益变动报告书 上市公司名称：西陇科学股份有限公司 股票简称：西陇科学 四、本次权益变动是根据本报告书所载明的资料进行的。信息披露义务人没 有委托或者授权任何其他人提供未在本报告书中列载的信息和对本报告书做出 任何解释或者说明。 五、信息披露义务人承诺本报告不存在虚假记载、误导性陈述或重大遗漏， 并对其真实性、准确性、完整性承担个别和连带的法律责任。 第 2 页 共 15 页 | | | 简式权益变动报告书签署日期：2025 年 10 月 31 日 第 1 页 共 15 页 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"证券法"）、 《上市公司收购管理办法》（以下简称"收购办法"）、《公开发行证券的公司信 息披露内容与格式准则第15号—权益变动报告书》（以下简称"准则15号"）及相 关的法律、法规编写本报告书。 ...

Core Viewpoint - The major shareholders of Xilong Science have reduced their holdings by a total of 3,540,700 shares, representing 0.605% of the company's total equity, due to personal financial needs and repayment of stock pledge financing [1] Group 1: Shareholding Changes - The reduction in shareholding occurred between October 29 and October 31, 2025 [1] - After the reduction, the major shareholders and their concerted actors hold a total of 146,304,022 shares, which is 25.00% of the total equity [1] - The reduction will not lead to a change in the company's controlling shareholder or actual controller, nor will it significantly impact the company's governance structure and ongoing operations [1] Group 2: Future Plans - As of the report date, the related reduction plan has not been fully implemented, and there is a possibility of further share changes based on personal arrangements [1]

Core Insights - Xilong Science is a leading domestic chemical reagent company with a full industry chain advantage, highlighting its investment value [1] Group 1: Financial Performance - In Q3 2025, Xilong Science achieved a revenue of 5.324 billion, ranking first among 35 companies in the industry, while the industry average was 1.399 billion [2] - The net profit for the same period was -60.94 million, placing it last in the industry, with the industry average net profit at 155 million [2] Group 2: Financial Ratios - As of Q3 2025, Xilong Science's debt-to-asset ratio was 56.30%, higher than the previous year's 53.08% and the industry average of 28.64% [3] - The gross profit margin for Q3 2025 was 7.52%, which, although an increase from 6.81% year-on-year, remained below the industry average of 31.60% [3] Group 3: Executive Compensation - The chairman, Huang Shaoqun, received a salary of 420,000, unchanged from 2023, while the president, Zhao Ye, saw an increase in salary to 623,700 from 499,900, reflecting a rise of 123,800 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.33% to 85,100, while the average number of circulating A-shares held per shareholder increased by 2.38% to 5,503.91 [5]

Group 1 - The core viewpoint of the news is that Xilong Science's stock has experienced fluctuations, with a recent decline in share price and significant net outflow of funds [1][2]. - As of October 29, Xilong Science's stock price was 8.37 CNY per share, with a market capitalization of 4.898 billion CNY [1]. - The company has seen a year-to-date stock price increase of 16.41%, but has faced declines of 3.57% over the last five trading days, 10.67% over the last 20 days, and 8.62% over the last 60 days [2]. Group 2 - Xilong Science has been listed on the "Dragon and Tiger List" five times this year, with the most recent net purchase of 3.6192 million CNY on September 24 [2]. - The company's main business involves the research, production, and sales of chemical reagents, with a revenue composition of 62.60% from specialized chemicals, 15.12% from chemical raw materials, and 9.66% from electronic chemicals [2]. - As of September 30, the number of shareholders was 85,100, a decrease of 2.33% from the previous period, while the average circulating shares per person increased by 2.38% to 5,503 shares [3]. Group 3 - For the period from January to September 2025, Xilong Science reported operating revenue of 5.324 billion CNY, a year-on-year decrease of 11.13%, and a net profit attributable to shareholders of -61.8292 million CNY, a decrease of 196.33% [3]. - The company has distributed a total of 217 million CNY in dividends since its A-share listing, with 31.0165 million CNY distributed in the last three years [4].

Market Overview - The electronic chemicals sector experienced a decline of 0.3% on October 28, with Siquan New Materials leading the drop [1] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Stock Performance - Notable gainers in the electronic chemicals sector included: - Huate Gas (688268) with a closing price of 68.52, up 5.42% on a trading volume of 44,800 shares and a turnover of 297 million [1] - Jingrui Electric Materials (300655) closed at 18.25, up 4.23% with a trading volume of 3.09 million shares and a turnover of 56.791 million [1] - Conversely, Siquan New Materials (301489) saw a significant decline of 16.98%, closing at 203.30 with a trading volume of 138,900 shares and a turnover of 298.5 million [2] Capital Flow - The electronic chemicals sector experienced a net outflow of 1.446 billion in main funds, while retail investors saw a net inflow of 1.253 billion [2] - The capital flow for specific stocks showed: - Dinglong Co. (300054) had a main fund net inflow of 37.85 million, but retail investors had a net outflow of 22.91 million [3] - Huate Gas (688268) experienced a main fund net inflow of 8.2143 million, with retail investors seeing a net outflow of 8.6272 million [3]

证券代码：002584 证券简称：西陇科学 公告编号：2025-053 1、以 9 票同意，0 票反对，0 票弃权的结果审议通过了《2025 年第三季度报 告》； 董事会认为，公司 2025 年第三季度报告的编制和审议程序符合法律、行政 法规、中国证监会和深圳证券交易所有关规定的要求，报告内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本报告已经公司董事会审计委员会审议通过。《西陇科学：2025 年第三季度 报告》具体内容详见与本公告同日刊登在《证券时报》、《中国证券报》、《上 海证券报》和《证券日报》及巨潮资讯网（http://www.cninfo.com.cn）公告。 西陇科学股份有限公司 第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西陇科学股份有限公司（以下简称"公司"）第六届董事会第十一次会议通知 于 2025 年 10 月 23 日以电话、专人送达方式通知公司全体董事，会议于 2025 年 10 月 27 日上午以现场和通讯相结合方式在公司五楼会 ...

Financial Performance - The company's operating revenue for the third quarter was ¥1,956,355,502.93, a decrease of 4.05% compared to the same period last year[5] - The net profit attributable to shareholders was ¥13,488,072.52, down 37.20% year-on-year, with a year-to-date loss of ¥61,829,221.42, representing a 196.33% decline[5] - The basic and diluted earnings per share were both ¥0.02, reflecting a decrease of 52.87% compared to the previous year[5] - Net profit for Q3 2025 was a loss of CNY 60,940,058.63, compared to a profit of CNY 65,009,643.51 in Q3 2024, indicating a significant decline[18] - The total comprehensive income attributable to the parent company was -61,829,024.65 yuan, compared to -10,321,881.13 yuan in the previous period, indicating a significant decline[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,143,596,251.76, an increase of 9.08% from the end of the previous year[5] - The company's total assets increased to CNY 5,143,596,251.76 from CNY 4,715,579,071.58, representing a growth of 9.06%[15] - Total liabilities rose to CNY 2,895,645,242.61, up from CNY 2,409,792,792.73, marking an increase of 20.19%[15] - The company's equity attributable to shareholders decreased by 2.50% to ¥2,242,209,964.81 compared to the end of the previous year[5] - The total equity attributable to shareholders decreased to CNY 2,242,209,964.81 from CNY 2,299,758,397.29, a decline of 2.49%[15] Cash Flow - The net cash flow from operating activities was ¥147,665,898.59, a significant increase of 401.70% year-to-date[5] - The net cash flow from operating activities was 147,665,898.59 yuan, an increase from 29,433,100.61 yuan year-over-year[20] - Cash inflow from operating activities totaled 6,391,267,670.87 yuan, down from 6,730,311,257.46 yuan in the previous period[20] - Cash outflow from operating activities was 6,243,601,772.28 yuan, compared to 6,700,878,156.85 yuan last year[20] - The net cash flow from investing activities was -30,651,676.45 yuan, an improvement from -106,275,775.86 yuan in the previous period[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 85,108[10] - The largest shareholder, Huang Shaoqun, holds 9.65% of shares, amounting to 56,500,000 shares, with 40,630,000 shares pledged[10] - The top 10 shareholders include significant individual stakeholders, with Huang Shaoqun, Huang Weipeng, and Huang Weibao being brothers and actual controllers of the company[10] Operating Expenses and Income - The company reported a significant increase in operating expenses, with non-operating expenses rising by 3698.96% to ¥117,164,870.19, primarily due to performance compensation provisions[8] - Other income decreased by 36.29% to ¥11,487,046.71, attributed to a reduction in government subsidies related to daily operations[8] - Research and development expenses for Q3 2025 were CNY 62,280,525.49, down from CNY 77,769,465.16, a reduction of 20.06%[17] Performance Compensation - The estimated compensation amount for the unfulfilled performance commitment from the equity transfer is ¥115,034,400[11] - The company has recognized a provision for the estimated liability of ¥64,634,400 related to the performance compensation[11] - The company experienced a 487.62% increase in estimated liabilities, mainly due to performance compensation provisions[8] - The company is currently negotiating with relevant parties regarding the performance compensation matter[11]